Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.

The regulation of cerebrovascular permeability is critical for normal brain homeostasis, and the "breakdown" of the blood-brain barrier (BBB) is associated with the development of vasogenic edema and intracranial hypertension in a number of neurological disorders. In this study we demonstrate that an increase in endogenous tissue-type plasminogen activator (tPA) activity in the perivascular tissue following cerebral ischemia induces opening of the BBB via a mechanism that is independent of both plasminogen (Plg) and MMP-9. We also show that injection of tPA into the cerebrospinal fluid in the absence of ischemia results in a rapid dose-dependent increase in vascular permeability. This activity is not seen with urokinase-type Plg activator (uPA) but is induced in Plg-/- mice, confirming that the effect is Plg-independent. However, the activity is blocked by antibodies to the LDL receptor-related protein (LRP) and by the LRP antagonist, receptor-associated protein (RAP), suggesting a receptor-mediated process. Together these studies demonstrate that tPA is both necessary and sufficient to directly increase vascular permeability in the early stages of BBB opening, and suggest that this occurs through a receptor-mediated cell signaling event and not through generalized degradation of the vascular basement membrane.

[1]  J. Garcìa,et al.  Neuronal ischemic injury: Light microscopy, ultrastructure and biochemistry , 1978, Acta Neuropathologica.

[2]  C. Siao,et al.  Cell Type-Specific Roles for Tissue Plasminogen Activator Released by Neurons or Microglia after Excitotoxic Injury , 2003, The Journal of Neuroscience.

[3]  Richard G. W. Anderson,et al.  LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.

[4]  J. Serena,et al.  Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke , 2003, Stroke.

[5]  I. Weissman,et al.  Tissue plasminogen activator and NMDA receptor cleavage , 2003 .

[6]  H. Birkedal‐Hansen,et al.  Collagen Dissolution by Keratinocytes Requires Cell Surface Plasminogen Activation and Matrix Metalloproteinase Activity* , 2002, The Journal of Biological Chemistry.

[7]  Michel Demeule,et al.  High transcytosis of melanotransferrin (P97) across the blood–brain barrier , 2002, Journal of neurochemistry.

[8]  A. Hand,et al.  Storage and release of tissue plasminogen activator by sympathetic axons in resistance vessel walls. , 2002, Microvascular research.

[9]  E. Lo,et al.  Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury: Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats , 2002, Stroke.

[10]  M. Chopp,et al.  Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke , 2002, Circulation.

[11]  T. Coleman,et al.  Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. , 2002, The Journal of clinical investigation.

[12]  Hartwig Wolburg,et al.  Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.

[13]  J. Herz,et al.  Proteolytic Processing of Low Density Lipoprotein Receptor-related Protein Mediates Regulated Release of Its Intracellular Domain* , 2002, The Journal of Biological Chemistry.

[14]  T. Hensch,et al.  Permissive proteolytic activity for visual cortical plasticity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Coughlin.  Protease-activated receptors in the cardiovascular system. , 2002, Cold Spring Harbor symposia on quantitative biology.

[16]  H. Bock,et al.  Lipoprotein receptors in the nervous system. , 2002, Annual review of biochemistry.

[17]  P. Sonderegger,et al.  Neuroserpin, a Neuroprotective Factor in Focal Ischemic Stroke , 2001, Molecular and Cellular Neuroscience.

[18]  M. Fini,et al.  Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia , 2001, The Journal of Neuroscience.

[19]  P. Bornstein,et al.  The Low Density Lipoprotein Receptor-related Protein Modulates Levels of Matrix Metalloproteinase 9 (MMP-9) by Mediating Its Cellular Catabolism* , 2001, The Journal of Biological Chemistry.

[20]  Alain Buisson,et al.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling , 2001, Nature Medicine.

[21]  M. Fini,et al.  Role for Matrix Metalloproteinase 9 after Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  T. Coleman,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Neuroserpin reduces cerebral infarct volume and protects neurons from , 2022 .

[23]  L. Badimón,et al.  LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  D. Holtzman,et al.  Role of Tissue Plasminogen Activator Receptor LRP in Hippocampal Long-Term Potentiation , 2000, The Journal of Neuroscience.

[25]  P. Carmeliet,et al.  Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[26]  P. Carmeliet,et al.  Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. , 1999, Circulation.

[27]  J. Koh,et al.  Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. , 1999, Science.

[28]  T. Betsuyaku,et al.  Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B. , 1999, American journal of respiratory cell and molecular biology.

[29]  L. Rubin,et al.  The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.

[30]  C. Sobey,et al.  Activation of protease-activated receptor-2 (PAR-2) elicits nitric oxide-dependent dilatation of the basilar artery in vivo. , 1998, Stroke.

[31]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[32]  G. Bu,et al.  Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family. , 1998, Current opinion in lipidology.

[33]  S. Lipton,et al.  Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.

[34]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[35]  L. Fenart,et al.  A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier , 1997, The Journal of cell biology.

[36]  T. Bugge,et al.  Loss of Fibrinogen Rescues Mice from the Pleiotropic Effects of Plasminogen Deficiency , 1996, Cell.

[37]  Gary A. Rosenberg,et al.  Proteolytic Cascade Enzymes Increase in Focal Cerebral Ischemia in Rat , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  P. Bickford,et al.  Tissue Plasminogen Activator Induction in Purkinje Neurons After Cerebellar Motor Learning , 1995, Science.

[39]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[40]  William G. Stetler-Stevenson,et al.  Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window , 1995, Brain Research.

[41]  Sidney Strickland,et al.  Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator , 1995, Nature.

[42]  A. M. Romanic,et al.  Extracellular Matrix‐Degrading Proteinases in the Nervous System , 1994, Brain pathology.

[43]  Eric R. Kandel,et al.  Tissue-plasminogen activator is induced as an immediate–early gene during seizure, kindling and long-term potentiation , 1993, Nature.

[44]  A. Schwartz,et al.  Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  O. Myklebost,et al.  Surface location and high affinity for calcium of a 500‐kd liver membrane protein closely related to the LDL‐receptor suggest a physiological role as lipoprotein receptor. , 1988, The EMBO journal.

[46]  L. Iversen,et al.  The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Baker Rn,et al.  The Movement of Exogenous Protein in Experimental Cerebral Edema An electron microscopic study after freeze-injury , 1971 .

[48]  P. Cancilla,et al.  THE MOVEMENT OF EXOGENOUS PROTEIN IN EXPERIMENTAL CEREBRAL EDEMA An electron microscopic study after freeze‐injury , 1971, Journal of neuropathology and experimental neurology.